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The effects of mutation of key active-site residues (Arg-47, Tyr-
51, Phe-42 and Phe-87) in Bacillus megaterium flavocytochrome
P450 BM3 were investigated. Kinetic studies on the oxidation of
laurate and arachidonate showed that the side chain of Arg-47
contributes more significantly to stabilization of the fatty acid
carboxylate than does that of Tyr-51 (kinetic parameters for
oxidation of laurate : R47A mutant, K
m
859 µM, k
cat
3960 min−" ;
Y51F mutant, K
m
432 µM, k
cat
6140 min−" ; wild-type, K
m
288 µM, k
cat
5140 min−"). A slightly increased k
cat
for the Y51F-
catalysed oxidation of laurate is probably due to decreased
activation energy (∆G‡) resulting from a smaller ∆G of substrate
binding. The side chain of Phe-42 acts as a phenyl ‘cap’ over the
mouth of the substrate-binding channel. With mutant F42A, K
m
is massively increased and k
cat
is decreased for oxidation of both
laurate (K
m
2.08 mM, k
cat
2450 min−") and arachidonate (K
m
34.9 µM, k
cat
14620 min−" ; compared with values of 4.7 µM and
17100 min−" respectively for wild-type). Amino acid Phe-87 is
critical for efficient catalysis. Mutants F87G and F87Y not only
exhibit increased K
m
and decreased k
cat
values for fatty acid
INTRODUCTION
The cytochromes P-450 (P450s) are a superfamily of haem
enzymes that are involved in an enormous array of oxidative
functions. They are found in organisms from all of the domains
of life [1,2], and multiple forms exist in eukaryotes [3]. The
eukaryotic forms are involved in several roles, including the
synthesis and interconversions of steroids, and the production of
prostaglandins and related eicosanoids [4]. Importantly, mam-
malian hepatic P450s play vital roles in the oxidation of drugs
and exogenous toxins, facilitating the excretion of the more polar
oxidized derivatives or targeting these molecules for subsequent
metabolism by ‘phase II ’ enzymes, such as glutathione S-
transferases or UDP-glucuronyltransferases [5]. Generally, fewer
P450s are found in lower eukaryotes and bacteria, although the
recent determination of the entire genome sequence of Myco-
bacterium tuberculosis indicated the presence of 21 P450 and
P450-like proteins [6]. In bacteria, the P450s have frequently
evolved to catalyse the oxidation of environmental organic
compounds, such as camphor, alkoxyphenols and herbicides,
allowing these materials to be used as growth substrates [2,7,8].
The bacterial P450s are soluble enzymes, whereas their
eukaryotic counterparts are generally integral membrane pro-
teins, as are their reductase systems. The relative ease of
overexpression, purification and crystallization of the bacterial
forms has led to the solution of the structures of six P450s to date
[2,9,10]. For two of these [the Pseudomonas putida camphor
Abbreviations used: P450, cytochrome P450 mono-oxygenase; ImC12, 12-(imidazolyl)dodecanoic acid ; 1-PIM, 1-phenylimidazole.
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oxidation, but also undergo an irreversible conversion process
from a ‘fast ’ to a ‘slow’ rate of substrate turnover [for F87G
(F87Y)-catalysed laurate oxidation: k
cat
‘ fast ’, 760 (1620) min−" ;
k
cat
‘ slow’, 48.0 (44.6) min−" ; k
conv
(rate of conversion from fast
to slow form), 4.9 (23.8) min−"]. All mutants showed less than
10% uncoupling of NADPH oxidation from fatty acid oxidation.
The rate of FMN-to-haem electron transfer was shown to become
rate-limiting in all mutants analysed. For wild-type P450 BM3,
the rate of FMN-to-haem electron transfer (8340 min−") is twice
the steady-state rate of oxidation (4100 min−"), indicating that
other steps contribute to rate limitation. Active-site structures of
the mutants were probed with the inhibitors 12-(imidazolyl)
dodecanoic acid and 1-phenylimidazole. Mutant F87G binds 1-
phenylimidazole " 10-fold more tightly than does the wild-type,
whereas mutant Y51F binds the haem-co-ordinating fatty acid
analogue 12-(imidazolyl)dodecanoic acid " 30-fold more tightly
than wild-type.
Key words: inhibition, kinetics, mutagenesis.
hydroxylase P450cam (CYP 101) and the Bacillus megaterium
fatty acid hydroxylase P450 BM3 (CYP 102A1)], the structures
of both substrate-bound and -free forms have been solved [11,12].
These structures provide templates for modelling eukaryotic
P450s, and provide the basis for rational site-directedmutagenesis
studies aimed at the elucidation of the roles of residues within the
active site [13,14] and others that are retained across different
branches of the P450 superfamily [15–17].
Arguably the most important model P450 is P450 BM3, a
high-activity fatty acid hydroxylase in which the P450 is fused to
its redox partner (a eukaryotic-like FAD- and FMN-containing
NADPH–P450 reductase) in a single polypeptide [18,19]. The
arrangement is analogous to that seen in the eukaryotic nitric
oxide synthases [20]. P450 BM3 hydroxylates a large range of
CC
"#
–C
#!
saturated and unsaturated fatty acids of carbon chain
length. It is the fastest P450 mono-oxygenase known, with rates
of over 5000 min−" for the best substrates (e.g. arachidonic acid)
[21]. The crystal structures of the substrate-free [11] and substrate
(palmitoleate)-bound [12] forms have allowed the identification
of a number of active-site residues likely to interact with sub-
strate or to be otherwise involved in the catalytic process. These
include: Arg-47 and Tyr-51, both of which are thought to
interact with the carboxylate group of fatty acid substrates
[12,14] ; Phe-87, which is known to undergo a dramatic movement
on substrate binding and to be vital in the control of the
regiospecificity of substrate oxidation [22,23] ; and Phe-42, which
is located at the mouth of the long, hydrophobic fatty-acid-
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Figure 1 Schematic representation of the relative positions of residues
Arg-47, Tyr-51, Phe-42 and Phe-87 in the active site of substrate
(palmitoleate)-bound P450 BM3
Residues Arg-47, Tyr-51 and Phe-42 are located at the ‘mouth ’ of the hydrophobic channel.
Arg-47 and Tyr-51 offer potential interactions with the carboxy group of the fatty acid, and Phe-
42 ‘ caps ’ the active site. Phe-87 lies above the haem ring and interacts with the ω-terminus
of fatty acid substrates. The dots around the palmitoleate indicate its van der Waals surface.
binding pocket of the P450, and which places a phenyl ‘cap’ over
the mouth of the active site (Figure 1).
In the present paper, we report the catalytic properties and
active-site structures of site-directed mutants of these key residues
using steady-state and stopped-flow enzyme kinetics, and by
spectrophotometric determinations of the affinities of binding of
fatty acids and imidazole inhibitors. These studies have allowed
us to evaluate the relative contributions of these residues to the
catalytic process of P450 BM3, and to form a clearer picture of
the mechanisms by which P450 BM3 regulates fatty acid oxidase
function.
EXPERIMENTAL
Materials
All P450 BM3 substrates and other reagents were purchased
from Sigma, and were of the highest grade available. The fatty
acids used were sodium laurate and arachidonic acid. Sodium
laurate (1 mM) was prepared in assay buffer (20 mM Mops}
100 mM KCl, pH 7.4), which was used throughout for kinetic
and binding studies. Arachidonic acid (33 mM or 3.3 mM) was
prepared in methanol}ethanol (1 :1, v}v). NADPH (20 mM) was
prepared in ice-cold assay buffer. 12-(Imidazolyl)dodecanoic
acid (ImC12) was synthesized andpurified as described previously
[24], and stock solutions (25–60 mM) were prepared in DMSO}
methanol (1 :1, v}v). 1-Phenylimidazole (1-PIM)was from Sigma,
and stocks (10 mM and 100 mM) were prepared in ethanol}
methanol (1 :1, v}v). Cytochrome c (horse heart ; type I) was
from Sigma.
Escherichia coli strains and plasmid vectors
E. coli strain TG1 [supE, hsd∆5, thi, ∆(lac-proAB), F« (traD36,
proAB+, lacIq, lacZ∆M15)] was used for all cloning work and for
overexpression of intact P450 BM3. The preparation of the
construct for the overexpression of intact P450 BM3 (plasmid
pBM23, also referred to previously as pJM23) has been described
in previous publications [19,25]. Plasmid clones encoding the
active-site mutants R47G, F87G and F87Y of P450 BM3 were
obtained from Dr. David Mullin and Professor William Alworth
(Department of Chemistry, Tulane University, New Orleans,
LA, U.S.A.) and overexpressed under a T7 promoter system
from plasmid vector pTZ18U in strain BL21 (DE3) [hsdS, gal
(λcIts857, ind1, Sam7, nin5, lacUV5-T7 gene 1)]. Mutants R47A,
Y51F and F42A were created by oligonucleotide-directed muta-
genesis of the pBM23 clone using the Kunkel method [26,27].
Single-stranded DNA was prepared using the helper phage M13
KO7 [28]. Oligonucleotide primers used in the mutagenesis
procedure were as follows (mismatches indicated by the under-
lined bases) : R47A, 5« GTAGCGCGTTACAGCACCAGGC-
GCCTCG 3« ; Y51F, 5« GACTTGATAAGAAGCGCGTTAC
3« ; F42A, 5« CCAGGCGCCTCGGCTTTAAAGATTTCTCC
3«. Mutants were overexpressed in strain TG1 in identical fashion
to the wild-type clone [25].
Enzyme preparations
Wild-type and mutant P450 BM3 enzymes were purified from E.
coli transformants in strains BL21 (DE3) (R47G, F87Y and
F87G) and TG1 (wild-type, R47A, Y51F and F42A) by growth
of the BL21 (DE3) transformant cultures (2–5 litres in Luria–
Bertani medium; 37 °C; shaking at 250 rev.}min) for 6–12 h after
induction at A
'!!
¯ 1 with 500 µg}ml isopropyl β--thiogalacto-
pyranoside, or by growth of the TG1 transformant cultures
(which express the P450 to high levels from the Bacillus promoter
in the stationary phase) for C 6 h after entry into stationary
phase. Wild-type P450 BM3 and mutant forms were purified by
column chromatography on DEAE-Sephacel and hydroxy-
apatite, as described previously [19,25]. A final gel-filtration step
(Sephacryl S-200HR) was used to remove minor contaminating
protein species. PMSF (1 mM) and leupeptin (1 mM) were added
to all buffers to minimize proteolysis. All proteins were stored at
®20 °C after two rounds of dialysis into successive 500-fold
volumes of buffer A (50 mM Tris}HCl, pH 7.5) containing 50%
(v}v) glycerol and protease inhibitors, and were used within 1
month of manufacture.
Spectrophotometric titrations of fatty acid substrate and inhibitor
binding
UV}visible absorption spectra were recorded over 300–800 nm
using a Shimadzu 2101 spectrophotometer and quartz cuvettes
of 1 cm path-length. Typically the concentration of wild-type or
mutant P450 BM3 used was 1–5 µM in 1 ml of assay buffer at
30 °C. For the titration of Y51F with ImC12, a much lower
enzyme concentration was required, due to the very high affinity
for the inhibitor (E 0.1 µM P450 used), and consequently a
5 cm-path-length cuvette was used. All spectral titrations were
performed at 30 °C. For enzyme titrations with sodium laurate,
10 µl aliquots of a 2 µM solution of P450 BM3 in assay buffer
were withdrawn and replaced with aliquots of a solution of
enzyme at identical concentration in the same buffer, but
containing in addition 1 mM sodium laurate. For the titrations
to determine the binding of arachidonic acid, ImC12 and 1-PIM,
small aliquots (0.1–0.4 µl ; less than 5 µl total addition) of stock
solution were added. Spectra were recorded after each addition
of substrate or inhibitor. Difference spectra were generated by
subtraction of each spectrum recorded from the original sub-
strate- or inhibitor-free spectrum. K
d
values were determined by
plotting the maximal absorbance changes calculated from each
difference spectrum against the concentration of substrate}
imidazole and fitting the data to a rectangular hyperbola using
Origin software (Microcal).
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Kinetic measurements
All steady-state kinetic experiments were performed at 30 °C in
assay buffer in 1 cm-path-length quartz cuvettes. Stopped-flow
experiments were performed using an Applied Photophysics
SF.17MV spectrophotometer.
Fatty acid oxidation
Fatty acid oxidation was determined as described previously
[29]. Initial rates of fatty acid (arachidonate, laurate) oxidation
were measured by monitoring the oxidation of NADPH at
340 nm (ε
$%!
6210 M−"[cm−") with 10–100 nM enzyme and
NADPH at saturating concentration (200 µM). The initial
arachidonate concentration was varied by the addition of small
volumes (! 2.0 µl) from the 33 mM or 3.3 mM alcoholic stock
using a Hamilton syringe (Hamilton, Reno, NV, U.S.A.), and
the initial laurate concentration was varied by dilution of the 1.1
mM aqueous stock. Rate measurements were converted into
activity units (mol of NADPH oxidized}min per mol of P450)
and plotted against fatty acid concentration, and the data were
fitted to the Michaelis–Menten equation using Origin.
Stopped-flow kinetic analysis of laurate oxidation by Phe-87 mutants
The steady-state conditions for the NADPH-dependent oxid-
ation of laurate (as described above) were set up on the
stopped-flow spectrophotometer to monitor the early stage of
the reaction catalysed by the F87Y and F87G mutant enzymes.
The progress curves obtained with initial laurate concentrations
of 50–950 µM for these reactions were fitted using the term
²P1[[1®e(−P#[t)}P2]´­P3[t, which describes a deactivation pro-
cess (exponential rate, P2) to a steady-state (linear) rate (P3)
from an initial (short) steady-state rate (P1) over time (t) [30].
Rates P1, P2 and P3 were each plotted against laurate con-
centration, and the data were fitted to the Michaelis–Menten
equation using Origin software.
Cytochrome c reduction
Initial rates of NADPH-dependent reduction of horse heart
cytochrome c catalysed by wild-type and mutant forms of P450
BM3 were measured at 550 nm (using ∆ε
&&!
¯ 22640 M−"[cm−"
for reduced-minus-oxidized cytochrome c) with 1–5 nM enzyme
and 200 µM NADPH.
Flavin-to-haem electron transfer
Measurement of the rate of flavin-to-haem electron transfer was
performed at 30 °C as described previously [25], using CO-
saturated buffers and monitoring formation of the ferrous-
iron–CO adduct at 450 nm. One syringe contained NADPH
(400 µM) and laurate (930 µM), and the second syringe contained
wild-type or mutant P450 BM3 (1–5 µM) and laurate (930 µM),
both in assay buffer previously deoxygenated (by bubbling
extensively with oxygen-free nitrogen) and saturated with CO by
bubbling for 5 min. Rates were obtained by fitting the progress
curves obtained to a single exponential process using the Applied
Photophysics software.
H2O2 titration
The extent of the uncoupling of NADPH oxidation from fatty
acid oxidation was assessed by titration of total H
#
O
#
formed
following complete oxidation of 200 µM NADPH by wild-type
or mutant forms of P450 BM3, with an initial laurate con-
centration of 950 µM and using the o-dianisidine}horseradish
peroxidase assay described by Macheroux et al. [31]. Following
complete oxidation of NADPH (monitored at 340 nm), o-
dianisidine was added (final concentration 8 mM) and the total
increase in absorbance at 440 nm due to formation of the o-
dianisidine radical dication oxidized product was measured after
addition of horseradish peroxidase (0.1 µM). This absorbance
value was converted into a concentration of o-dianisidine
oxidized using the known coefficient (∆ε
%%!
¯ 11600 M−"[cm−") ;
this equals the H
#
O
#
concentration.
RESULTS
Fatty acid binding and kinetics of fatty acid oxidation
Wild-type P450 BM3
The substrates laurate and arachidonate were used to assess the
effects of active-site mutation on substrate binding and kinetic
characteristics. Previous studies have shown that laurate binding
to wild-type P450 BM3 induces a low- to high-spin state shift of
! 30% at saturating concentrations of laurate [21,32], that
binding is characterized by a K
d
of approx. 90–110 µM (e.g. [15]),
and that steady-state kinetic measurements of laurate mono-
oxygenation yield a k
cat
of E 1200 min−" and a K
m
of E 100 µM
at 30 °C (e.g. [33,34]). In a previous paper, we reported a k
cat
of
1252 min−" and a K
m
of 89 µM for laurate mono-oxygenation,
which yields a k
cat
}K
m
of 14.1 µM−"[min−" [34]. For these
previous experiments, the sodium laurate stock solution (50 mM)
was prepared in ethanol, such that kinetic measurements were
performed in the presence of low (but significant) concentrations
of ethanol (0.02–0.5%, v}v). In the present study, we prepared
a 1.1 mM solution of laurate in assay buffer (near the solubility
limit) to permit rate measurements at laurate concentrations up
to E 1 mM and to eliminate the uncertainty in rate measurement
brought about by the presence of organic solvent.
The induced spectral shifts on the haem Soret band of P450
BM3 in aqueous 1 mM laurate remained at E 30% (spectra not
shown), but a spectrophotometric titration yielded a K
d
some
2.5-fold higher (241 µM) with aqueous laurate than with the
alcoholic stock. Kinetic measurements of laurate oxidation,
monitored by following the initial rate of oxidation of NADPH
at 340 nm and using dilutions of the 1 mM aqueous stock to
obtain the Michaelis–Menten curve, yielded parameters with
higher values than those obtained with the alcoholic laurate
stock. The curve is characterized by a K
m
of 288 µM and a k
cat
of 5140 min−" (Figure 2). It is important to note that the k
cat
}K
m
for this experiment (17.8 µM−"[min−") is similar to that obtained
using the previous method.
The low- to high-spin shift of the haem Soret band induced
upon binding of arachidonate to P450 BM3 is much larger than
that for laurate (typically " 90% conversion at a saturating
concentration of arachidonate) [21], and the binding is much
stronger (K
d
¯ 3.6 µM). The rate of arachidonate oxidation is
also much higher. In the present study, we have determined a k
cat
of 17100 min−" and a K
m
of 4.7 µM, from measurements of the
initial rates of arachidonate-induced NADPH oxidation. Thus
the k
cat
}K
m
for this oxidation is 3640 µM−"[min−".
Mutants R47A and R47G
The guanidinium of Arg-47 at the mouth of the substrate-
binding site (Figure 1) is thought to provide an important ion-
pair interaction with the fatty acid carboxylate group [12].
Removal of this group by mutation of Arg-47 has deleterious
effects on the binding and catalytic characteristics of the enzyme.
For both the R47A and R47G mutants, the low- to high-spin
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Figure 2 Michaelis–Menten curves for the NADPH-dependent oxidation of
sodium laurate catalysed by wild-type flavocytochrome P450 BM3 (D) and
mutants Y51F (_), R47G (E) and F42A (+)
Initial rates were determined by monitoring the oxidation of NADPH at 340 nm at 30 °C in assay
buffer, as described in the Experimental section. The data are characterized by the following
parameters : wild-type P450, Km 288³15 µM, kcat 5140³90 min−
1 ; R47G, Km 648³50 µM,
kcat 2745³95 min−
1 ; Y51F, Km 432³20 µM, kcat 6140³120 min−
1 ; F42A, Km
2.08³0.38 mM, kcat 2450³580 min−
1.
conversion induced by binding of laurate or arachidonate is
considerably less than for the wild-type enzyme. The kinetic
parameters (k
cat
, K
m
and k
cat
}K
m
) are presented in Table 1. There
is an increase in K
m
and a decrease in k
cat
for the oxidation of
laurate and arachidonate by both Arg-47 mutants as compared
with the wild-type (Figure 2). The K
m
and k
cat
values for the
R47A-catalysed oxidations are greater than those with the R47G
mutant, but the k
cat
}K
m
values for the two mutants are similar,
and demonstrate 4- and 7-fold decreases in catalytic efficiency
over wild-type for the oxidation of laurate and arachidonate
respectively.
Mutant Y51F
The hydroxy group of Tyr-51 has also been implicated in
stabilization of the fatty acid carboxylate group via a hydrogen-
bond interaction. Indeed, it has been postulated to provide a
more important interaction than that of Arg-47 [12]. However,
we found that removal of the hydroxy group in mutant Y51F
had less detrimental effects on the catalytic parameters than
those observed with the R47A}G mutants. The predominant
Table 1 Kinetic parameters for oxidation of laurate and arachidonate catalysed by wild-type and mutant flavocytochromes P450 BM3
Initial-rate measurements of the oxidation of NADPH were performed at 30 °C in assay buffer (20 mM Mops/100 mM KCl, pH 7.4), as described in the Experimental section.
Laurate oxidation Arachidonate oxidation
Enzyme Km (µM) kcat (min−
1) kcat/Km (µM−
1[min−1) Km (µM) kcat (min−
1) kcat/Km (µM−
1[min−1)
Wild-type 288³15 5140³90 17.8³1.4 4.70³0.25 17100³190 3640³245
R47A 859³79 3960³180 4.6³0.7 18.8³3.9 10640³750 566³198
R47G 648³50 2745³95 4.2³0.6 9.8³1.7 4855³210 495³130
Y51F 432³20 6140³120 14.2³1.0 14.8³1.8 14040³520 949³171
F42A 2080³380 2450³580 1.18³0.6 34.9³2.7 14620³490 419³50
effect is on K
m
values for the oxidation of both laurate and
arachidonate by Y51F (Figure 2). For laurate oxidation, the K
m
is 1.5-fold greater than the wild-type value (Table 1), while there
is a slight increase in k
cat
(6140 min−"). For arachidonate oxid-
ation, K
m
is 3-fold greater than wild-type, while k
cat
is only 18%
lower (14040 min−"). The effect on k
cat
}K
m
for fatty acid oxidation
catalysed by Y51F is only a 1.25-fold decrease for laurate
oxidation and a 3.8-fold decrease for arachidonate oxidation
relative to the oxidations catalysed by the wild-type enzyme
(Table 1). These data demonstrate that Tyr-51 is less important
than Arg-47 in the enzyme–substrate interaction.
Mutant F42A
The phenyl group of Phe-42 lies across the mouth of the substrate-
binding channel of P450 BM3 [11], and appears to act as a
hydrophobic ‘ lid ’ over the active site (Figure 1). Of the three
residues that we have mutated at the mouth of the active site, the
most dramatic effects on substrate binding and on the catalytic
parameters for substrate oxidation were observed with F42A.
The low- to high-spin shift induced in the Soret band by 1 mM
sodium laurate is very small (! 5%). For the F42A-catalysed
oxidation of laurate, the K
m
is increased more than 7-fold over
wild-type (to " 2 mM) (Figure 2). Up to the limit of solubility of
sodium laurate in the assay buffer (E 1 mM), the increase in rate
is still almost linear with concentration, and a best fit of the
Michaelis–Menten equation to the data yields a k
cat
of E
2450 min−". The value of k
cat
}K
m
is 15-fold lower than that for
the wild-type enzyme (Table 1). Laurate does not induce a large
enough spin-state shift in F42A to enable the determination of a
K
d
for this substrate.Arachidonate does induce partial conversion
into the high-spin form (E 35% at 66 µM arachidonate), and the
K
d
is 19.3³1.3 µM. As with laurate oxidation, there is a 7-fold
increase in K
m
for arachidonate oxidation by F42A, but the k
cat
(14620 min−") is similar to the wild-type value. The k
cat
}K
m
is
decreased 9-fold relative to that for wild-type (Table 1).
Cytochrome c reduction kinetics
To ensure that mutations made in the haem domain did not
influence the electron-transfer properties of the diflavin domain,
we determined the kinetic characteristics of the reduction of
cytochrome c catalysed by wild-type and mutant P450 BM3
enzymes. Initial rates of reduction were measured with 2.0–60 µM
cytochrome c, and the steady-state rates (mol of cytochrome c
reduced}min per mol of P450) were plotted against cytochrome
c concentration. There was little variation in either k
cat
or K
m
for
the reduction catalysed by the mutants as compared with the
wild-type (K
m
within range 12.0³3.0 µM; k
cat
within range
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Figure 3 Progress curve for the oxidation of NADPH (at 340 nm) catalysed
by the F87G mutant of P450 BM3 in the presence of sodium laurate, using
stopped-flow kinetics
The reaction was followed using stopped-flow kinetics at 30 °C in assay buffer. Initial
concentrations of NADPH and sodium laurate in the mixing chamber were 200 µM and
930 µM respectively, and the enzyme concentration was 0.26 µM. The form of the progress
curve observed for F87G was also seen for the F87Y-mutant-catalysed reactions. The
absorbance–time data collected using the stopped-flow spectrophotometer are represented as
dots, and the solid line is the best fit to the term ²P1[[1®e(−P2[t )/P2]´­P3[t, which
describes an initial ‘ fast ’ steady state (P1) followed by a deactivation process (exponential rate ;
P2) to a ‘ slow ’ steady-state rate (P3) [30]. Rates P1, P2 and P3 correspond to 596 mol/min
per mol, 4.0 min−1 and 40 mol/min per mol respectively. The kinetic parameters describing the
laurate-concentration-dependence of each of these rates for the F87G and F87Y mutants are
given in Table 2.
14000³2000 min−") (results not shown). These small differences
are likely to be attributable to some variations in the FMN
content in the enzyme preparations. The FMN cofactor is
essential for efficient transfer to cytochrome c, but is the more
weakly bound flavin [35], and a small proportion will be lost
during purification.
Kinetic behaviour of Phe-87 mutants
The reaction progress for the oxidation of laurate catalysed by
wild-type P450 BM3 and by Arg-47, Tyr-51 and Phe-42 mutants
followed true steady-state kinetics, i.e. exhibiting a linear
absorbance change until substrate depletion}product accumu-
lation became significant. However, we have noted that the
steady-state kinetic behaviour of oxidation catalysed by both
the F87Y and F87G mutants is unusual. Rather than ob-
serving the expected linear behaviour of the initial stage of the
Table 2 Kinetic characteristics of the oxidation of sodium laurate catalysed by F87G and F87Y mutant flavocytochromes P450 BM3
Reactions were performed at 30 °C in assay buffer. Progress curves of the oxidation of NADPH, obtained by stopped-flow kinetics at 340 nm, were fitted to the term ²P1[[1®e(−P2[t )/P2]´­P3[t,
which describes an initial ‘ fast ’ steady-state rate (P1) followed by a deactivation process (exponential rate ; P2) to a ‘ slow ’ steady-state rate (P3) [30] (see Figure 3). Rates P1, P2 and P3 were
each plotted against laurate concentration, and the data were fitted to the Michaelis–Menten equation. The term kconv is the maximum rate of conversion to the ‘ slow ’ oxidizing form of F87G/Y,
while Kc is the laurate concentration at 0.5¬kconv.
‘ Fast ’ steady state ‘Slow ’ steady state Conversion
Mutant P450 BM3 Km (µM) kcat (min−
1) Km (µM) kcat (min−
1) Kc (µM) kconv (min−
1)
F87G 476³195 760³140 290³60 48.0³3.7 213³65 4.9³0.5
F87Y 42.3³9.0 1620³50 84.4³13.5 44.6³1.4 268³120 23.8³3.6
reaction, the reaction progress was noticeably non-linear over
this period, subsequently entering a much slower linear phase.
This behaviour was assessed in more detail using stopped-flow
kinetics. The experimental design using the stopped-flow system
was identical to that for the conventional spectrophotometric
steady-state assays, i.e. monitoring the progress of the oxidation
of laurate by measuring NADPH oxidation at 340 nm. The
stopped-flow apparatus was set up so that reactions could be
followed using a split time base, with a short initial phase
(10–20 s) followed by a much longer second phase (typically "
200 s). Data were collected over a concentration range of
50–950 µM laurate. A typical reaction trace is shown in Figure 3.
The form of the progress curves obtained suggested that the
oxidation reactions catalysed by the F87Y and F87G mutants
were characterized by an initial, short (fast) steady-state phase
followed by an irreversible exponential conversion to yield a
second (slower) steady-state phase. Analysis of the data using an
equation describing such a process [30] (see the Experimental
section) gave good fits. Plots of the two steady-state rates (‘ fast ’
and ‘slow’) and the conversion rate thus determined against
laurate concentration showed adherence to Michaelis–Menten
kinetics. The kinetic parameters characterizing both the F87Y-
and F87G-catalysed reactions are shown in Table 2. These
results suggest that the Phe-87 mutants undergo an irreversible
conformational change during catalytic turnover which results in
decreased catalytic competence.
Stopped-flow measurement of flavin-to-haem electron transfer
The rate of electron transfer from flavin to haem in fatty acid-
bound P450 BM3 is conveniently measured using CO-saturated
buffers and monitoring the formation of the ferrous iron–CO
adduct at 450 nm using stopped-flow kinetics [25]. Binding of CO
to ferrous P450 BM3 is extremely rapid (k
on
C 4¬10' M−"[s−" at
20 °C), although binding of dioxygen may occur considerably
faster [36]. We measured the rates of flavin-to-haem electron
transfer at 30 °C by rapid mixing of CO-saturated solutions of
(a) NADPH (400 µM) and laurate (930 µM) with (b) wild-type
or mutant P450 BM3 enzymes (1–5 µM) and laurate (930 µM).
The data were compared directly with the steady-state rates
measured by monitoring NADPH oxidation (Table 3). The rates
of flavin-to-haem transfer in all the mutants were lower than for
the wild-type enzyme. Indeed, for all the mutants, the stopped-
flow rate observed for the first electron transfer to the haem was
decreased to a value very similar to the steady-state rate. This
indicates that flavin-to-haem electron transfer is the major rate-
limiting step in laurate oxidation catalysed by these mutants. For
the F87Y and F87G mutants, the flavin-to-haem transfer rate
corresponded to the steady-state rate of NADPH oxidation
catalysed by the ‘ fast ’ form of the enzyme (Table 2). However,
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Table 3 Flavin-to-haem electron transfer rates for wild-type flavo-
cytochrome P450 BM3 and mutants, obtained by stopped-flow kinetics
Flavin-to-haem electron transfer rates were measured as a kobs at 930 µM laurate. These rates
are compared with the steady-state rates of NADPH oxidation at 930 µM laurate by wild-type
and mutant enzymes. Stopped-flow measurements of the formation of the Fe2+–CO adduct at
450 nm were performed in CO-saturated buffer containing 200 µM NADPH and 930 µM
laurate at 30 °C in assay buffer, as described in the Experimental section. * Indicates that values
are derived from the Michaelis–Menten curve for the ‘ fast ’ oxidizing forms of F87G and F87Y.
P450 BM3
Flavin-to-haem electron
transfer rate (min−1)
Steady-state rate of NADPH
oxidation (mol/min per mol)
Wild-type 8340³50 4100³150
R47A 1660³20 2000³90
R47G 1716³20 1600³85
Y51F 3740³50 4000³130
F42A 606³5.0 650³30
F87G 885³30 500³30*
F87Y 1600³125 1480³70*
in the case of the wild-type enzyme, we have measured a flavin-
to-haem transfer rate that is 2-fold faster than the steady-state
rate (k
obs
8340 min−", compared with 4100 mol}min per mol),
indicating that other steps along the catalytic pathway may also
limit the rate.
Determination of uncoupling in wild-type and mutant enzymes
The measurement of total H
#
O
#
formed during the oxidation of
all available NADPH under steady-state oxidation of laurate
was carried out by direct titration using an o-dianisidine}
horseradish peroxidase assay [31] (see the Experimental section).
This is a convenient and accurate method, since it avoids the
errors associated with fatty acid oxidation product recovery and
quantification. Using this method, we have measured the extent
of uncoupling of NADPH oxidation to be 3.8% for the wild-
type-enzyme-catalysed oxidation of laurate. For all mutants, the
Figure 4 Absorbance difference spectra recorded during the titration of wild-type P450 BM3 (2 µM) with 1-PIM (2–334 µM)
The binding of 1-PIM results in a shift of the Soret band of the P450 from 419 nm to 424 nm in the absolute spectrum. In the difference spectra, the maximal absorbance changes (∆Abs.) induced
at each concentration of 1-PIM [absorbance change at 427 nm (∆A427)®absorbance change at 393 nm (∆A393)] are plotted against 1-PIM concentration, and the data are fitted to the Michaelis
function (inset), as described in the Experimental section. This yields the Kd for binding of the ligand (10.4 µM in this case).
extent of uncoupling never exceeded 8%, except in the case of
F87Y (10%). In the case of the Y51F-mutant-catalysed reaction,
it was found that NADPH oxidation was exceptionally well
coupled to laurate oxidation (only 0.16% H
#
O
#
formed).
Binding of ImC12 and 1-PIM to wild-type and mutant P450 BM3
We have described previously the potent inhibitory properties of
imidazolyl fatty acids on the catalytic behaviour of P450 BM3,
and their binding characteristics towards both substrate-free and
substrate-saturated enzyme forms [37]. In the present study, we
have measured the affinity of both ImC12 and the tight-binding
1-PIM for the wild-type enzyme and mutants Y51F, F42A,
R47A}G and F87G}Y to probe the active-site environment. The
nitrogen atom of the imidazole moieties of ImC12 and 1-PIM
ligates to the ferric haem, causing a type II shift in the Soret band
from 419 to 424 nm (Figure 4), but the affinity of the interaction
is modulated by the surrounding active-site structure. K
d
values
were determined by plotting these induced spectral changes
against imidazole concentration, as described in the Experimental
section (Table 4). Binding of ImC12 to wild-type P450 BM3 is
characterized by a K
d
of 8.0 µM. Binding is much weaker to the
Arg-47 mutants (e.g. K
d
42.2 µM for R47G), due to removal of
the interaction between the fatty acid carboxylate group and the
guanidinium group of Arg-47. Remarkably, the affinity of ImC12
for Y51F is considerably stronger than that for the wild-type
enzyme (K
d
0.22 µM). This could be due to loss of a hydrogen
bond between the hydroxy group of Tyr-51 and the guanidinium
group of Arg-47, resulting in an increase in cationic charge on
Arg-47 available for interaction with the carboxy group of
ImC12. The removal of the phenyl group of Phe-42 also has the
effect of increasing the affinity for ImC12 (K
d
2.5 µM for F42A).
This may be due to an increased accessibility to the haem for this
inhibitor. The tighter binding of ImC12 to mutants Y51F and
F42A relative to the wild-type enzyme contrasts with the catalytic
situation, where the K
m
values for these two mutants with laurate
are increased (E 1.5-fold for Y51F, but " 7-fold in the case
of F42A). K
d
values for the binding of laurate to mutants Y51F
and F42A cannot be determined spectrophotometrically, because
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Table 4 Dissociation constants for the binding of ImC12 and 1-PIM to wild-
type and mutant flavocytochromes P450 BM3
Titrations were performed spectrophotometrically at 30 °C in assay buffer. Details of the
experimental design and the treatment of the spectral data to obtain the Kd values are given
in the Experimental section. *Indicates that the titration was performed using a 5 cm path-length
cuvette.
Kd (µM)
P450 BM3 ImC12 1-PIM
Wild-type 8.0³0.2 10.4³0.4
R47A 35.4³1.2 4.2³0.1
R47G 42.2³1.0 6.7³0.3
Y51F 0.22³0.01* 8.3³0.6
F42A 2.5³0.2 7.3³0.2
F87G 5.3³0.1 0.8³0.03
F87Y 24.3³2.6 7.1³1.1
the spin-state shifts observed in the Soret bands are too small.
However, we have been able to determine K
d
values for binding
of arachidonate to the F42A and Y51F mutants, since the
spectral changes accompanying binding are much larger. Binding
of arachidonate to F42A mutant P450 BM3 is characterized by
a K
d
of 19.3³1.3 µM, considerably weaker than binding to wild-
type (K
d
3.6 µM). By contrast, binding of arachidonate to the
Y51F mutant is tighter (K
d
0.68 µM), although the extent of the
induced spin-state shift as a result of this binding (C 50%) is not
as great as in the wild-type enzyme (" 90%).
Binding of 1-PIM to wild-type P450 BM3 is characterized by
a K
d
of 10.4 µM, i.e. weaker than the binding to the mutant
forms (Table 4). Mutants R47A, R47G, Y51F and F42A all
display slightly increased affinities towards 1-PIM (K
d
values in
the range 4.2–8.3 µM), presumably due to improved accessibility
to the haem. The most notable effect on binding is observed with
the F87G mutant, where the affinity is increased 13-fold over
wild-type (K
d
0.8 µM). The removal of the Phe-87 phenyl group
may leave a hydrophobic space in which the phenyl group of 1-
PIM can bind efficiently, explaining the very tight ligation of
1-PIM to this mutant.
DISCUSSION
In this study, we have determined the kinetic consequences of the
mutation of important active-site residues in flavocytochrome
P450 BM3. In particular, we have resolved the relative con-
tributions of the side chains of Arg-47 and Tyr-51 to fatty acid
binding and catalysis. This pair of residues forms a hydroxy–
guanidinium interaction at the mouth of the fatty-acid-binding
channel, and both associate with the carboxy group of the fatty
acid substrate. The decreases in k
cat
and increases in K
m
for the
oxidation of laurate and arachidonate catalysed by the R47A
and R47G mutant enzymes relative to wild-type demonstrates
that the electrostatic interaction between the Arg-47 guanidinium
group and the fatty acid carboxy group is involved in both initial
binding and transition-state stabilization. In contrast, for the
Y51F-mutant-catalysed oxidations, the K
m
is increased but k
cat
is
essentially unaffected, showing that the hydrogen-bonding in-
teraction between the hydroxy group of Tyr-51 and the fatty acid
carboxy group is important only for initial binding. It should be
emphasized that contributions other than those from Arg-47 and
Tyr-51 are important to the binding of fatty acids in the P450
BM3 active site. Indeed, if the ion-pair interaction between Arg-
47 and the fatty acid carboxylate was the main stabilizing factor
in the binding of fatty acid substrate, then much larger increases
in the K
m
and K
d
values for fatty acid substrates would be
expected with the mutants [38]. However, other favourable
interactions occur between the fatty acid alkyl chain and multiple
hydrophobic amino acids (such as Leu-181 and Leu-437) in the
long channel leading down from Arg-47}Tyr-51 to the haem.
The major purpose of the interactions between the fatty acid
carboxylate group and Arg-47}Tyr-51 is likely to be in the
correct positioning of substrate to promote efficient active-site
dehydration and the accompanying haem iron spin-state con-
version which is critical for catalysis [21].
The presence of both a positively charged amino acid and a
hydroxy-group-containing amino acid (Arg-47 and Tyr-51 in
P450 BM3) interacting with the carboxylate of a substrate
molecule is an active-site motif that is conserved in certain other
enzymes, and the catalytic effects (increased K
m
, but similar k
cat
)
of the removal of the hydroxy moiety of this pairing are similar
to those that we have observed in P450 BM3. For example, the
tetrameric -lactate cytochrome c oxidoreductase (flavocyto-
chrome b
#
) from Saccharomyces cereisiae uses Arg-376 and Tyr-
143 to stabilize the binding of lactate. The flavocytochrome b
#
mutant Y143F shows a 6-fold increased K
m
and an unchanged
k
cat
relative to wild-type using -lactate as a substrate and
ferricyanide as the electron acceptor [39,40]. The motif is also
conserved in flavocytochrome b
#
from Hansenula anomala (Arg-
362 and Tyr-135) [41] and in the closely related Rhodotorula
graminis -mandelate dehydrogenase (Tyr-25 and Arg-277),
which is also a tetrameric flavocytochrome [42]. Similarly,
mutation Tyr-24!Phe in spinach glycolate oxidase (containing
Tyr-24 and Arg-257 in the active site) results in a 10-fold
increased K
m
and an unchanged k
cat
for glycolate oxidation [43].
In Bacillus stearothermophilus lactate dehydrogenase, a serine
residue (Ser-163) replaces tyrosine in hydrogen-bonding to the
the lactate, but the hydroxy amino acid motif is retained [44]. In
this enzyme, Arg-171 is the analogue of Arg-47 in P450 BM3.
Mutant R171K of the lactate dehydrogenase exhibits much
higher K
m
and lower k
cat
values than the wild-type enzyme [45].
Again, this is similar to the effects that we observed on the
catalytic parameters of the R47G}A mutants of P450 BM3 [45].
The spin-state shifts induced by the binding of arachidonate to
the R47G and Y51F mutants of P450 BM3 are sufficient to allow
determination of K
d
values : R47G, K
d
7.1 µM, spin-shift E
20% ; Y51F, K
d
0.68 µM, spin-shift E 35%. Arachidonate
binding to the wild-type enzyme is characterized by a K
d
of
3.6 µM and results in a " 90% spin-state shift. Hence the
affinity of arachidonate for the Y51F mutant appears to be
higher than that for the wild-type, while that for the R47G
mutant is lower. It is very interesting to note that the K
d
values
for fatty acid substrate and imidazole-linked fatty acid (ImC12)
binding to Y51F are decreased relative to wild-type, whereas the
K
m
values for Y51F-catalysed substrate oxidation are increased
(Tables 1 and 4). Most notable is the huge (30-fold) increase in
the affinity of the Y51F mutant for ImC12. For the R47A}G and
Y51F mutants, the extent of the low-to-high spin-state shift
induced by binding of fatty acid is considerably lower than for
the wild-type enzyme. Despite the higher affinity for Y51F, the
binding mode adopted by the fatty acid does not result in
efficient active-site desolvation, and the Y51F haem iron popu-
lation remains substantially low-spin, i.e. with the aqua (6th)
ligand still present. These results demonstrate that the interaction
between the fatty acid carboxy group and the hydroxy group of
Tyr-51 is essential to induce the efficient low-to-high spin-state
shift required for elevation of the haem reduction potential [21].
We postulate that the absence of the hydroxy group of Tyr-51
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has the effect of strengthening the electrostatic interaction
between the guanidinium of Arg-47 and the carboxylate group of
the substrate, resulting in higher apparent affinity, but also in a
different binding mode from which the 6th (aqua) haem ligand
cannot be displaced efficiently. The observation that trends in K
d
values for substrate}inhibitor binding do not reflect the trends in
K
m
values for substrate oxidation emphasizes the point that the
K
d
is purely a single equilibrium binding constant determined by
spectrophotometric titration of the oxidized enzymes, whereas
the K
m
(determined under steady-state turnover conditions) is a
complex term comprising multiple binding constants throughout
the catalytic pathway.
In the structure of the substrate-free P450 BM3 haem domain
[11], the phenyl side chain of Phe-42 lies close to the mouth of the
active site at the protein surface. However, in the substrate-
bound form the side chain is repositioned and ‘caps ’ the mouth
of the binding site, effectively protecting the substrate in its
hydrophobic environment and probably also strengthening the
electrostatic interaction between the substrate carboxy group
and the guanidinium group of Arg-47 by excluding solvent
water. The catalytic effects of mutation of this residue are
dramatic. The predominant effect is on K
m
. For the F42A-
catalysed oxidations of both laurate and arachidonate, the K
m
is
increased " 7-fold over that with the wild-type enzyme, whereas
the k
cat
is decreased 2-fold (laurate) and 1.2-fold (arachidonate).
There is a consequent large decrease in k
cat
}K
m
(15- and 9-fold
for laurate and arachidonate respectively). We believe that the
F42A mutation leaves the active site more exposed to solvent,
resulting in considerable weakening of the guanidinium–carboxy
interaction. However, such large effects on catalytic parameters
are not observed for Arg-47-mutant-catalysed fatty acid oxid-
ations, for which the guanidinium–carboxy interaction is absent.
This suggests that the F42A mutation has other consequences.
The phenyl group of Phe-42 may form a key part of the
hydrophobic surface, which also comprises residues Phe-11, Leu-
14, Leu-17, Pro-18 and Leu-19, and which has been suggested to
be a fatty acid recognition}docking region [11,46]. Both the
increased access of water and the absence of a substrate-
recognition amino acid would be expected to have effects on K
m
.
However, the absence of the phenyl ‘cap’ allows easier access of
ImC12 to the active-site pocket, which is reflected in the 3-fold
decrease in the K
d
for this inhibitor (Table 4).
The structures of the substrate-free and -bound forms of P450
BM3 show that large conformational changes occur on substrate
binding, with a narrowing of the binding pocket around the
substrate and considerable re-orientation of several active-site
side chains [12]. One such side-chain motion involves the phenyl
group of Phe-87, which rotates from a conformation almost
perpendicular to the haem plane in the substrate-free form to lie
parallel when substrate is bound. NMR paramagnetic relaxation
studies have shown that, upon reduction of the ferric iron, the
substrate moves some 6 AI (0.6 nm) closer to the haem [47]. This
movement must be accompanied by further conformational
changes also involving Phe-87, but the nature of these changes is
unknown. Phe-87 is known to control the regiospecificity of fatty
acid oxidation. Oliver et al. [23] reported that mutant F87A
hydroxylates laurate at the terminal (ω) position, whereas wild-
type P450 BM3 hydroxylates mainly at ω®2. The mutant retains
good laurate oxidation activity, indicating that substitution of
the phenyl ring for a methyl group retains sufficient hydro-
phobicity to allow interaction with the terminal part of the alkyl
chain of the fatty acid. We have shown that the rates of laurate
oxidation catalysed by both the F87G and F87Y mutants are
considerably lower than that with the wild-type enzyme. For
F87G, this may be due to the absence of favourable hydrophobic
binding interactions with the terminus of the alkyl chain, while
for F87Y such interactions could be disrupted by the presence of
the tyrosine hydroxy group. Crucially, Phe-87 also appears to be
instrumental in facile conformational switching of the enzyme
during the catalytic cycle. Our results suggest that both the F87Y
and F87G mutants undergo an irreversible deactivation process
during catalysis of laurate oxidation, from an initial ‘ fast ’ oxi-
dizing form, through an exponential conversion into a ‘slow’
oxidizing form. We can propose two possibilities to explain this
behaviour. First, there may be an irreversible conformational
change during turnover. Alternatively, there may be a change in
the rate-limiting step, either to a conformational-switching limit
or to a product-release limit. In wild-type- and Arg-47}Tyr-
51}Phe-42-mutant-catalysed reactions, conformational switch-
ing is rapid. Immediately after its formation, the oxidation
product must still be protected within the active site, and rapid
conformational changes occur which cause it to be released. The
first flavin-to-haem electron transfer is observable as the main
determinant of the overall rate (as demonstrated by the stopped-
flowkinetic studies of flavin-to-haem electron transfer). However,
for the F87G- and F87Y-mutant-catalysed reactions, we pos-
tulate that the rapid conformational switching mechanism lead-
ing to product release is disrupted. The product is held by a
relatively long-lived conformer of the enzyme that exists towards
the end of the catalytic cycle, so that its release (or the
conformational readjustment to regain resting enzyme) is rate-
limiting. By such a process, the slow reaction phase (Figure 3)
retains linear steady-state characteristics over the time course we
have measured. The concentration of oxidized product in the
bulk solvent over this time period is too low to have a competitive
inhibitory effect on the steady state, and so we do not observe a
progressively decreasing rate.
In conclusion, the present studies have elucidated the roles of
four important active-site residues in flavocytochrome P450
BM3. Residue Tyr-51 was postulated to provide the dominant
contribution in binding the fatty acid carboxylate group [12], but
our studies indicate that Arg-47 provides a stronger stabilizing
interaction. However, the interaction between the fatty acid and
Tyr-51 appears to be important for substrate-induced haem iron
spin-state shift, which is critical to catalysis [21]. In addition to
controlling the regioselectivity of substrate oxidation [23], we
have identified a key role for Phe-87 in the conformational
switches that occur during the catalytic cycle of P450 BM3
[12,47]. Mutants F87G and F87Y both undergo conversion into
a low-activity form during turnover. We postulate that this is due
to an alteration in the rate-limiting step in catalysis from a flavin-
to-haem electron transfer step to product release, as a conse-
quence of these mutations. We are currently investigating this
phenomenon further. The most severe effects on catalytic
efficiency are observed in mutant F42A, due to the removal of
the phenyl ‘cap’ from the top of the active site. The mutants
F42A}Y51F and F87G bind the fatty-acid-linked azole ImC12
and the smaller inhibitor 1-PIM respectively much more tightly
than does wild-type P450 BM3, indicating that considerable
reorganization of the active site is induced by these mutations.
We are currently performing crystallographic trials with the
mutant haem domains and investigating further the substrate
preferences of these mutants in order to define the nature of these
structural changes and their consequences.
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